{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:41:28Z","timestamp":1781811688749,"version":"3.54.5"},"reference-count":29,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/jmno9568","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T03:10:35Z","timestamp":1713841835000},"page":"679-695","source":"Crossref","is-referenced-by-count":3,"title":["Regulating TKT activity inhibits proliferation of human acute lymphoblastic leukemia cells"],"prefix":"10.62347","volume":"14","author":[{"given":"Fang-Liang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","unstructured":"Van Vlierberghe P and Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 2012; 122: 3398-3406.","journal-title":"J Clin Invest"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/imr.12237","article-title":"Epigenetics in T-cell acute lymphoblastic leukemia","volume":"263","author":"Peirs","year":"2015","unstructured":"Peirs S, Van der Meulen J, Van de Walle I, Taghon T, Speleman F, Poppe B and Van Vlierberghe P. Epigenetics in T-cell acute lymphoblastic leukemia. Immunol Rev 2015; 263: 50-67.","journal-title":"Immunol Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1002\/cncr.29573","article-title":"Childhood acute lymphoblastic leukemia: integrating genomics into therapy","volume":"121","author":"SK","year":"2015","unstructured":"Tasian SK, Loh ML and Hunger SP. Childhood acute lymphoblastic leukemia: integrating genomics into therapy. Cancer 2015; 121: 3577-3590.","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1586\/ehm.10.73","article-title":"Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches","volume":"3","author":"Tanosaki","year":"2010","unstructured":"Tanosaki R and Tobinai K. Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches. Expert Rev Hematol 2010; 3: 743-753.","journal-title":"Expert Rev Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions","volume":"13","author":"Samra","year":"2020","unstructured":"Samra B, Jabbour E, Ravandi F, Kantarjian H and Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol 2020; 13: 70.","journal-title":"J Hematol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14728214.2016.1257606","article-title":"Emerging biological therapies to treat acute lymphoblastic leukemia","volume":"22","author":"Huguet","year":"2017","unstructured":"Huguet F and Tavitian S. Emerging biological therapies to treat acute lymphoblastic leukemia. Expert Opin Emerg Drugs 2017; 22: 107-121.","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5483\/BMBRep.2018.51.7.112","article-title":"Cancer stem cell metabolism: target for cancer therapy","volume":"51","author":"Chae","year":"2018","unstructured":"Chae YC and Kim JH. Cancer stem cell metabolism: target for cancer therapy. BMB Rep 2018; 51: 319-326.","journal-title":"BMB Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-016-0555-x","article-title":"Cancer stem cell metabolism: a potential target for cancer therapy","volume":"15","author":"Deshmukh","year":"2016","unstructured":"Deshmukh A, Deshpande K, Arfuso F, Newsholme P and Dharmarajan A. Cancer stem cell metabolism: a potential target for cancer therapy. Mol Cancer 2016; 15: 69.","journal-title":"Mol Cancer"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Gill KS, Fernandes P, O’Donovan TR, McKenna SL, Doddakula KK, Power DG, Soden DM and Forde PF. Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response. Biochim Biophys Acta 2016; 1866: 87-105.","DOI":"10.1016\/j.bbcan.2016.06.005"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13046-019-1131-1","article-title":"Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner","volume":"38","author":"Qin","year":"2019","unstructured":"Qin Z, Xiang C, Zhong F, Liu Y, Dong Q, Li K, Shi W, Ding C, Qin L and He F. Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner. J Exp Clin Cancer Res 2019; 38: 154.","journal-title":"J Exp Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10585-015-9718-1","article-title":"Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation","volume":"32","author":"Ricciardelli","year":"2015","unstructured":"Ricciardelli C, Lokman NA, Cheruvu S, Tan IA, Ween MP, Pyragius CE, Ruszkiewicz A, Hoffmann P and Oehler MK. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin Exp Metastasis 2015; 32: 441-455.","journal-title":"Clin Exp Metastasis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.7150\/jca.15467","article-title":"Transketolase serves a poor prognosticator in esophageal cancer by promoting cell invasion via epithelial-mesenchymal transition","volume":"7","author":"Chao","year":"2016","unstructured":"Chao YK, Peng TL, Chuang WY, Yeh CJ, Li YL, Lu YC and Cheng AJ. Transketolase serves a poor prognosticator in esophageal cancer by promoting cell invasion via epithelial-mesenchymal transition. J Cancer 2016; 7: 1804-1811.","journal-title":"J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/CAD.0b013e328013d99e","article-title":"The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells","volume":"18","author":"LH","year":"2007","unstructured":"Hu LH, Yang JH, Zhang DT, Zhang S, Wang L, Cai PC, Zheng JF and Huang JS. The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells. Anticancer Drugs 2007; 18: 427-433.","journal-title":"Anticancer Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3892\/or.2021.8241","article-title":"Niclosamide suppresses T-cell acute lymphoblastic leukemia growth through activation of apoptosis and autophagy","volume":"47","author":"Huang","year":"2022","unstructured":"Huang FL, Yu SJ, Liao EC, Li LY, Shen PW and Li CL. Niclosamide suppresses T-cell acute lymphoblastic leukemia growth through activation of apoptosis and autophagy. Oncol Rep 2022; 47: 30.","journal-title":"Oncol Rep"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Faubert B, Solmonson A and DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science 2020; 368: eaaw5473.","DOI":"10.1126\/science.aaw5473"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"113607","DOI":"10.1016\/j.biopha.2022.113607","article-title":"The role of transketolase in human cancer progression and therapy","volume":"154","author":"Hao","year":"2022","unstructured":"Hao S, Meng Q, Sun H, Li Y, Li Y, Gu L, Liu B, Zhang Y, Zhou H, Xu Z and Wang Y. The role of transketolase in human cancer progression and therapy. Biomed Pharmacother 2022; 154: 113607.","journal-title":"Biomed Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41419-022-04575-5","article-title":"Transketolase promotes colorectal cancer metastasis through regulating AKT phosphorylation","volume":"13","author":"Li","year":"2022","unstructured":"Li M, Zhao X, Yong H, Xu J, Qu P, Qiao S, Hou P, Li Z, Chu S, Zheng J and Bai J. Transketolase promotes colorectal cancer metastasis through regulating AKT phosphorylation. Cell Death Dis 2022; 13: 99.","journal-title":"Cell Death Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.7150\/jca.69583","article-title":"Transketolase serves as a biomarker for poor prognosis in human lung adenocarcinoma","volume":"13","author":"Niu","year":"2022","unstructured":"Niu C, Qiu W, Li X, Li H, Zhou J and Zhu H. Transketolase serves as a biomarker for poor prognosis in human lung adenocarcinoma. J Cancer 2022; 13: 2584-2593.","journal-title":"J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Heiden MG","year":"2009","unstructured":"Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/cr.2011.145","article-title":"K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis","volume":"22","author":"Hu","year":"2012","unstructured":"Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao PJ, Keating MJ, Garcia-Manero G and Huang P. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 2012; 22: 399-412.","journal-title":"Cell Res"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H, Luo Y and Huang P. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol 2012; 10: e1001326.","DOI":"10.1371\/journal.pbio.1001326"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1535-7163.MCT-12-0131","article-title":"A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo","volume":"11","author":"Liu","year":"2012","unstructured":"Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J and Chen X. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 2012; 11: 1672-1682.","journal-title":"Mol Cancer Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/jcp.20166","article-title":"Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer","volume":"202","author":"ML","year":"2005","unstructured":"Macheda ML, Rogers S and Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654-662.","journal-title":"J Cell Physiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1038\/onc.2011.454","article-title":"2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines","volume":"31","author":"Zagorodna","year":"2012","unstructured":"Zagorodna O, Martin SM, Rutkowski DT, Kuwana T, Spitz DR and Knudson CM. 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines. Oncogene 2012; 31: 2738-2749.","journal-title":"Oncogene"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"21354","DOI":"10.1038\/s41598-021-98642-0","article-title":"Metabolic profiling of attached and detached metformin and 2-deoxy-D-glucose treated breast cancer cells reveals adaptive changes in metabolome of detached cells","volume":"11","author":"Repas","year":"2021","unstructured":"Repas J, Zügner E, Gole B, Bizjak M, Potočnik U, Magnes C and Pavlin M. Metabolic profiling of attached and detached metformin and 2-deoxy-D-glucose treated breast cancer cells reveals adaptive changes in metabolome of detached cells. Sci Rep 2021; 11: 21354.","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"16116","DOI":"10.3390\/ijms232416116","article-title":"Niclosamide as a promising therapeutic player in human cancer and other diseases","volume":"23","author":"Wang","year":"2022","unstructured":"Wang Z, Ren J, Du J, Wang H, Liu J and Wang G. Niclosamide as a promising therapeutic player in human cancer and other diseases. Int J Mol Sci 2022; 23: 16116.","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","article-title":"Development of therapeutic combinations targeting major cancer signaling pathways","volume":"31","author":"TA","year":"2013","unstructured":"Yap TA, Omlin A and de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013; 31: 1592-1605.","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Tourneau C","year":"2009","unstructured":"Le Tourneau C, Lee JJ and Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009; 101: 708-720.","journal-title":"J Natl Cancer Inst"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc1300","article-title":"Cancer as a robust system: implications for anticancer therapy","volume":"4","author":"Kitano","year":"2004","unstructured":"Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004; 4: 227-235.","journal-title":"Nat Rev Cancer"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/2\/ajcr0153878.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:52:34Z","timestamp":1766022754000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/2\/ajcr0153878.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/jmno9568","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3326583\/v1","asserted-by":"object"}]},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}